AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01669733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Recorded or live music will be played prior to surgery in the preoperative room. Subjects in the live music group and subjects in the recorded music group will listen to recorded music intraoperatively. An ipod with headphones will be given to the subject when she is being prepared to move to the operating room. The board certified music therapist will initiate recorded music (harp selections). Recorded music will be relaxing harp selections. The board certified music therapist will accompany the subject to the operating room and assure volume levels and electronic equipment function properly.
Study NCT01669733 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The control group subjects will receive standard anesthesia, nursing and surgical care.
Study NCT02394847 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: propofol
Study NCT04057014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic given at different dosages and durations.
Study NCT04057014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: Removal of infected tooth on first day of study, this approach does not require an antibiotic drug.
Study NCT04057014 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extraction
Description: Removal of infected tooth on first day of study, this approach does not require an antibiotic drug.
Study NCT06168110 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation (TENS) is a non-invasive treatment method widely used for pain control
Study NCT06168110 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation (TENS) is a non-invasive treatment method widely used for pain control
Study NCT04106661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Physical activity requiring slow, controlled whole body movement and weight shifting.
Study NCT03829787 — intervention group
Intervention type: DEVICE
Intervention: Eye tracking
Description: Subjects will be assessed for attentional biases, reward sensitivity, and cognitive control using eye tracking technology
Study NCT03116191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 weeks of repeated administration of Placebo to the patients of nocturia
Study NCT04489576 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Keratin hair treatment (Keratin Cure ®) versus (QOD Max ®)
Description: Hair will be treated with 2 different types of keratin in groups 1 \& 2. All steps of keratin application will be done in group 3 without keratin application as a control group.
Study NCT04489576 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Keratin hair treatment (Keratin Cure ®) versus (QOD Max ®)
Description: Hair will be treated with 2 different types of keratin in groups 1 \& 2. All steps of keratin application will be done in group 3 without keratin application as a control group.
Study NCT00748891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recentin (Cediranib)
Description: 30mg once daily, oral dose
Study NCT04329585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flumazenil
Description: EEG is observed in both groups to compare the difference between two groups.
Study NCT04329585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo is the normal saline, which is given in the controlled group.
Study NCT02518399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat therapy
Description: Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions. In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C for 60min.
Study NCT04039607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenvatinib
Description: Participants will receive lenvatinib as oral capsules.
Study NCT01341301 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Undergo TBI
Study NCT01341301 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: Undergo DLI
Study NCT01341301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01341301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT01341301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Given IV or PO
Study NCT01341301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic HSCT
Study NCT01341301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory biomarker analysis
Description: Correlative studies
Study NCT03752268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhancing Cancer Pain Management
Description: Patients will learn and practice an enduring framework of cognitive-behavioral strategies, to enhance adherence behavior, reduce intentional and unintentional deviations from the prescribed regimen.
Study NCT03622021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK111 or Placebo
Description: All the subjects in each cohort will be randomized in a 3:1 ratio to receive either AK111 or Placebo.
Study NCT00706329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deflux
Description: Patients undergo surgery using Deflux to correct umbilical hernia
Study NCT03085511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Egg breakfast (EB)
Description: Breakfast is considered as high quality protein diet, but has similar weight, energy, and macronutrients as the active comparator. The details are as follows: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.6%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.
Study NCT03085511 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Counseling
Description: Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics will include portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, as well as behavioral strategies including self-monitoring, motivational interviewing, goal setting, and problem solving.
Study NCT03085511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Counseling
Description: Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics will include portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, as well as behavioral strategies including self-monitoring, motivational interviewing, goal setting, and problem solving.
Study NCT03085511 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Diet
Description: Participants will have a 1200-1500kcals diet based on each individual's body weight during the study.
Study NCT03085511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Diet
Description: Participants will have a 1200-1500kcals diet based on each individual's body weight during the study.
Study NCT03085511 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cereal Breakfast (CB)
Description: Breakfast is considered as low quality protein diet, but has similar weight, energy, and macronutrients as that in experimental group. The details are as follows: weight 293 g, energy 398 kcal, energy density 1.36 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.
Study NCT00378911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally
Study NCT01709942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix (long acting GnRH antagonist)
Description: 20 mg of degarelix the first day of menstrual cycle before starting with gonadotrophins administration
Study NCT01709942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetrorelix 0.25mg
Description: 0.25mg of cetrorelix during treatment with gonadotrophins when estradiol levels were >300pg/ml
Study NCT00966290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulant (warfarin, acenocoumarol, fluindione)
Description: Anticoagulant clinic based shared-care group
Study NCT00966290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulant (warfarin, acenocoumarol, fluindione)
Description: Usual care group
Study NCT03225261 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrus extract
Description: Citrus extract
Study NCT03225261 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study NCT04151251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Empowerment
Description: Group to receive a 5 minute video about typical hospital sleep disruptions and what they can do to prevent them, as well as a brochure outlining the importance of sleep
Study NCT04151251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Kit
Description: Patients receive a small pouch that includes an eye mask, ear plugs, and headphones, all to be used to aid in falling/staying asleep
Study NCT04151251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Kit
Description: Patients receive a small pouch that includes an eye mask, ear plugs, and headphones, all to be used to aid in falling/staying asleep
Study NCT02466113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A 6 microRNA stratified tool
Description: Investigators randomly assign patients to be assessed by a 6 microRNA stratified tool. MicroRNA(miRNA) tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miRNA-21-5p)+(0.086×status of miRNA-20a-5p)+(0.240×status of miRNA-103a-3p)+(0.095×status of miRNA-106b-5p)-(0.238×status of miRNA-143-5p)-(0.237×status of miRNA-215),low expression status equals 0 and high expression status equals 1). Investigators defined high risk patient if their score larger than 1, the others as low risk patient.The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
Study NCT03972280 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
Description: Recombinant anti-G-CSF receptor monoclonal antibody is a preservative-free, sterile liquid formulation that is suitable for intravenous infusion
Study NCT04347239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos
Study NCT04347239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leronlimab (700mg)
Description: Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Study NCT02619292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Movement Program
Description: Mindfulness is turning one's awareness to the present moment. Movement-dance therapy is the expression of thoughts or feelings through body movement, under the supervision of a licensed professional.
Study NCT03945396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homeopathic Medication
Description: A homeopathic mineral medicine, form of impure calcium carbonate, CaCO3, which can be found in nature in different niches, from limestone to eggshells.
Study NCT03945396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention (Exercise program, diet, motivational support)
Description: Exercise program: includes a five-times per week routine: warm-up during 10 to 15 minutes, then 40 minutes of aerobic exercise that will be increased progressively until reaching 60 minutes. Thereafter, muscular strength initiating 5%, and increasing until 10 to 15% of body weight. Then, 10 to 15 minutes of stretching. Finally, 5 min cool-down.~Diet: Subjects will receive a balance diet calculated based on energetic needs according FAO: 15-20% of proteins, 50-60% of carbohydrate, 20-25% of fat per day.~Motivational support: 50 min session where empathy and neutral understanding of the perspective and feelings of the adolescent, and his family, are fostered to motivate the change and to state realistic goals in reducing weight.
Study NCT03945396 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary intervention (Exercise program, diet, motivational support)
Description: Exercise program: includes a five-times per week routine: warm-up during 10 to 15 minutes, then 40 minutes of aerobic exercise that will be increased progressively until reaching 60 minutes. Thereafter, muscular strength initiating 5%, and increasing until 10 to 15% of body weight. Then, 10 to 15 minutes of stretching. Finally, 5 min cool-down.~Diet: Subjects will receive a balance diet calculated based on energetic needs according FAO: 15-20% of proteins, 50-60% of carbohydrate, 20-25% of fat per day.~Motivational support: 50 min session where empathy and neutral understanding of the perspective and feelings of the adolescent, and his family, are fostered to motivate the change and to state realistic goals in reducing weight.
Study NCT03945396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Homeopathic placebo
Description: A 30 ml bottle of 30% alcohol-distilled water.
Study NCT01712607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Warm-Up training
Description: Preoperative Warm-Up training
Study NCT00875225 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DVD
Description: Control group will receive usual care DVD from health professionals
Study NCT00875225 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention DVD
Description: Intervention group will receive intervention DVD with patient stories and information from health care professionals
Study NCT04043091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous coronary intervention (stenting)
Description: percutaneous stent implantation in coronary artery
Study NCT02518399 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Thermoneutral water immersion
Description: Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions. In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
Study NCT03168230 — intervention group
Intervention type: PROCEDURE
Intervention: Portal vein embolization (PVE)
Description: Portal vein embolization (PVE) is a procedure that induces regrowth on one side of the liver in advance of a planned hepatic resection on the other side. The procedure is frequently used in primary liver cancer (hepatocellular carcinoma) and colorectal liver metastases.~An interventional radiologist will place a needle percutaneously (through the skin) into the liver and identify the blood vessel on the side where the largest part of the tumor is being supplied. Tiny microspheres are then infused into the portal vein which supplies blood to the area, embolizing it by cutting off its blood supply.~This blockade of the blood supply induces the other side of the liver to regrow. After several weeks, the non-embolized side has grown enough so that surgery is now a viable option.~Source of this information : http://general.surgery.ucsf.edu/conditions--procedures/portal-vein-embolization-(pve).aspx
Study NCT01716975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124
Description: Arms 1, 2
Study NCT00453544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Consent Procedure
Description: This is a procedure involving use of multimedia materials, as well as standard review with research staff, to see if the research consent procedure can be improved
Study NCT00453544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Consent Procedure
Description: This is a procedure designed to be in accord with standard research consent practices (and lacks multimedia aids)
Study NCT01359657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CXCR4 (BMS-936564)
Description: Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 42 days (cycle 1) 28 days subsequent cycles
Study NCT01359657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Tablets, per os (by mouth route of administration) (P.O), 25 mg, daily for 21 days (Day 15-35 in cycle 1; Day 1-21 in subsequent cycles), no dosing in Cycle 1, Cycle 2 +:daily dosing from Day 1-21
Study NCT01359657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered with Lenalidomide once every 7 days, 42 days (cycle 1) 28 days subsequent cycles
Study NCT01359657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CXCR4 (BMS-936564)
Description: Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 35 days (cycle 1) 21 days subsequent cycles
Study NCT01359657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Intravenous (IV), 1.3 mg/m2, administered on day 15, 18, 22, 25 in cycle 1, then on Day 1, 4, 8, 11 in subsequent cycles, no dosing in Cycle 1, Cycle 2 +:dosing on Day 1, 4, 8, 11
Study NCT01359657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered on the day of (and the day after) Bortezomib infusion, 35 days (cycle 1) 21 days subsequent cycles
Study NCT03434054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: blood pressure medication
Study NCT03434054 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-active sham intervention
Study NCT01331954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic ablation device
Description: One or two HIFU procedures
Study NCT00534274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3'-deoxy-3'-[18F]fluorothymidine
Study NCT02223273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted Strategy
Description: 1. Simulation Based Team Training~2. Case Manager: a trained person who works in the hospital and is responsible for ensuring the usage of all interventions~3. Reminders -~4. Check lists - decision support algorithm~5. Distribution of educational materials: guidelines and recommendations for best practices
Study NCT00362115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil
Description: Azilsartan medoxomil 5 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Study NCT00362115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil
Description: Azilsartan medoxomil 10 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Study NCT00362115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil
Description: Azilsartan medoxomil 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Study NCT00362115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil
Description: Azilsartan medoxomil 40 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Study NCT00362115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil
Description: Azilsartan medoxomil 80 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Study NCT00362115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: Olmesartan 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Study NCT00362115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets, orally, once daily for up to 8 weeks.
Study NCT01558752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total hip replacement with titanium shell and CORAIL stem
Description: Patients that are randomized into Group 1 will receive a total hip replacement with the following components: CORAIL (impaction broach) titanium stem and a monoblock cup with ceramic on ceramic bearing (DELTA motion).
Study NCT01558752 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip replacement with Modular Titanium Femoral Stem
Description: Patients that are randomized into Group 2 will receive a total hip replacement with the following components: the Trilock-Pinnacle system (titanium stem and titanium cup with polyethylene insert).